Core Viewpoint - Haitong International reports that the main business revenue and profit of CSPC Pharmaceutical Group (01093) have bottomed out, with expectations to return to an upward cycle by 2026 and benefit from the launch of innovative oncology and metabolic products starting in 2027 [1] Group 1: Revenue and Profit Outlook - The potential milestone revenue for CSPC Pharmaceutical Group is estimated at $5.8 billion (approximately RMB 40.6 billion), which is expected to gradually enhance the company's profits over the next 3-5 years [1] - The firm believes that upfront payments and milestone revenues will provide sustainable recurring income for the company, leading to an upward revision of the revenue forecast for authorized products post-2027 [1] Group 2: R&D and Collaboration - CSPC Pharmaceutical Group has achieved seven external collaboration deals in the past two years, with total upfront payments of $1.71 billion and potential milestone revenues exceeding $30 billion [2] - The company has partnered with AstraZeneca three times, highlighting its R&D platform's global influence and value [2] - The firm is optimistic about CSPC's ability to generate regular income through milestone sales and net revenue sharing throughout the drug lifecycle [2] Group 3: Pipeline and Technology - CSPC's small nucleic acid platform has a broad layout, targeting popular liver delivery points such as PCSK9, AGT, and ANGPTL3, and is ahead of domestic peers in development [3] - The company has applied for patents related to lipid delivery and specific siRNA treatments, indicating potential advancements in neurological and ocular delivery technologies [3] - The SYS6010 (EGFR-ADC) has accumulated clinical data from over a thousand patients, showing potential for best-in-class efficacy and safety [4] Group 4: Clinical Developments - The company has initiated a Phase III clinical trial for SYS6010 in China for first-line treatment of non-small cell lung cancer (NSCLC) and plans to advance global Phase III trials [4] - CSPC's in vivo CAR-T product, SYS6055, has received clinical approval in China, representing the first in vivo CAR-T product approved domestically, with potential advantages in cost and accessibility [4] Group 5: Financial Projections - The firm has adjusted revenue forecasts for FY25, FY26, and FY27 to RMB 26.7 billion, 28.9 billion, and 30.6 billion respectively, reflecting changes in the recognition of upfront payments [5] - The net profit forecasts for FY25, FY26, and FY27 have been revised to RMB 4.4 billion, 4.6 billion, and 5.3 billion respectively [6]

Group 1: Financial Performance - The overall operating performance for 2025 is in line with the annual business plan, with specific results to be disclosed later [1] - The gross profit margin for the first three quarters of this year is approximately 29%, with a goal to continue improving this margin [3] Group 2: Market and Production Capacity - In 2025, the Chinese innovative drug market transaction amount exceeded $1.3 billion, boosting domestic market enthusiasm and demand, although competition remains strong with no significant price changes [1] - The overall capacity utilization rate of the company improved in 2025, focusing on utilizing existing capacity and assets, with capital expenditures (Capex) aimed at enhancing specific capabilities and facility upgrades [2][3] Group 3: Business Development and Innovation - The company achieved significant breakthroughs in various business areas, including commercial process changes and the development of in vivo CAR-T projects, with successful deliveries in overseas markets such as the US, Europe, and South Korea [3][4] - The company currently has a pilot-scale production capacity for small nucleic acids, sufficient to meet clinical phase II demand [5] Group 4: Operational Efficiency - The company aims to maintain a direction of cost reduction and efficiency improvement, with a net increase in personnel in 2025 while controlling expense growth in line with revenue increases [7]

Core Insights - The company is focused on innovative approaches in the field of in vivo CAR-T therapy, emphasizing its unique position in a competitive landscape [1] - The primary asset of interest is SC451, aimed at providing a functional cure for type 1 diabetes, a condition affecting approximately 9 million individuals [2] Company Overview - The company was founded on two main ideas: evading immune detection of cells and delivering specific payloads to targeted cells in vivo [2] - The development of SC451 is a significant focus, indicating the company's commitment to addressing unmet medical needs in diabetes treatment [2]